Imugene raises A$11.1M to push allogeneic CAR-T through key trials
What's the deal? ImugeneDealroom has a profile for this one. Try Dealroom →, an ASX-listed clinical-stage immuno-oncology company, has completed an A$11.1 million placement to fund its lead asset, azer-cel — an off-the-shelf CAR-T therapy targeting CD19 in blood cancers. The raise involved roughly 117.1 million new shares at A$0.095 each. Bell Potter Securities acted as lead manager and bookrunner.
Who's backing it? The placement drew new and existing institutional investors, including long-only global funds. A global, commercial-stage biopharmaceutical company subscribed for about 14% of the placement, subject to shareholder approval, and Imugene directors also participated on the same basis.
Why now? The raise follows early data from the BTK inhibitor plus azer-cel combination cohort of Imugene's Phase 1b study, which reported complete responses in the first two evaluable patients. Those results strengthen the case for azer-cel in patients whose disease progressed after BTKi therapy — a market Imugene values at over US$12 billion a year.
What's the endgame? The money mainly funds azer-cel through clinical and regulatory milestones, plus working capital, extending Imugene's runway into calendar 2027. The company expects further readouts from the combination and CAR-T naïve cohorts through early-to-mid 2027, with data slated for the ASH 2026 and ASCO 2027 conferences.
Imugene took global rights to azer-cel from Precision BioSciences in 2025 and has been reshaping its cost base around the asset. It views the coming stretch of data as pivotal for business development talks and potential collaborations.
What could go wrong? The clinical signals rest on small patient numbers, and both the biopharma subscription and director participation still need shareholder approval. Turning early responses into a competitive, off-the-shelf product will require far larger, later-stage trials.
The signal: This is a targeted, program-enabling raise rather than a routine top-up — a quick re-raise tied to a single, potentially pivotal asset. It positions Imugene to compete in the CD19 CAR-T space as larger players pour money into allogeneic and next-generation cell therapies.
Read more: Finance News Network
Image credit: Montage Communications
